Latest news with #LifeVantage
Yahoo
3 days ago
- Business
- Yahoo
Here's Why LifeVantage (NASDAQ:LFVN) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. In contrast to all that, many investors prefer to focus on companies like LifeVantage (NASDAQ:LFVN), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Even modest earnings per share growth (EPS) can create meaningful value, when it is sustained reliably from year to year. So it's easy to see why many investors focus in on EPS growth. Impressively, LifeVantage's EPS catapulted from US$0.29 to US$0.73, over the last year. It's not often a company can achieve year-on-year growth of 154%. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that LifeVantage is growing revenues, and EBIT margins improved by 4.1 percentage points to 5.8%, over the last year. Both of which are great metrics to check off for potential growth. You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image. See our latest analysis for LifeVantage In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of LifeVantage's forecast profits? It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own LifeVantage shares worth a considerable sum. To be specific, they have US$30m worth of shares. This considerable investment should help drive long-term value in the business. That amounts to 19% of the company, demonstrating a degree of high-level alignment with shareholders. LifeVantage's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering LifeVantage for a spot on your watchlist. Of course, just because LifeVantage is growing does not mean it is undervalued. If you're wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Although LifeVantage certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
25-05-2025
- Business
- Yahoo
LifeVantage Corporation (NASDAQ:LFVN) Goes Ex-Dividend Soon
Readers hoping to buy LifeVantage Corporation (NASDAQ:LFVN) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date occurs one day before the record date, which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Therefore, if you purchase LifeVantage's shares on or after the 30th of May, you won't be eligible to receive the dividend, when it is paid on the 13th of June. The company's next dividend payment will be US$0.045 per share. Last year, in total, the company distributed US$0.16 to shareholders. Based on the last year's worth of payments, LifeVantage has a trailing yield of 1.3% on the current stock price of US$12.66. If you buy this business for its dividend, you should have an idea of whether LifeVantage's dividend is reliable and sustainable. So we need to investigate whether LifeVantage can afford its dividend, and if the dividend could grow. We check all companies for important risks. See what we found for LifeVantage in our free report. If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. LifeVantage is paying out just 21% of its profit after tax, which is comfortably low and leaves plenty of breathing room in the case of adverse events. A useful secondary check can be to evaluate whether LifeVantage generated enough free cash flow to afford its dividend. The good news is it paid out just 17% of its free cash flow in the last year. It's positive to see that LifeVantage's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. Check out our latest analysis for LifeVantage Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. This is why it's a relief to see LifeVantage earnings per share are up 6.6% per annum over the last five years. Earnings per share have been growing at a decent rate, and the company is retaining more than three-quarters of its earnings in the business. This is an attractive combination, because when profits are reinvested effectively, growth can compound, with corresponding benefits for earnings and dividends in the future. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, three years ago, LifeVantage has lifted its dividend by approximately 10% a year on average. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders. Has LifeVantage got what it takes to maintain its dividend payments? Earnings per share have been growing moderately, and LifeVantage is paying out less than half its earnings and cash flow as dividends, which is an attractive combination as it suggests the company is investing in growth. It might be nice to see earnings growing faster, but LifeVantage is being conservative with its dividend payouts and could still perform reasonably over the long run. There's a lot to like about LifeVantage, and we would prioritise taking a closer look at it. Curious what other investors think of LifeVantage? See what analysts are forecasting, with this visualisation of its historical and future estimated earnings and cash flow. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Statutory Profit Doesn't Reflect How Good LifeVantage's (NASDAQ:LFVN) Earnings Are
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's (NASDAQ:LFVN) stock has recently. We have done some analysis, and we found several positive factors beyond the profit numbers. We've discovered 1 warning sign about LifeVantage. View them for free. Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. LifeVantage has an accrual ratio of -0.27 for the year to March 2025. Therefore, its statutory earnings were very significantly less than its free cashflow. Indeed, in the last twelve months it reported free cash flow of US$12m, well over the US$9.15m it reported in profit. LifeVantage shareholders are no doubt pleased that free cash flow improved over the last twelve months. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Happily for shareholders, LifeVantage produced plenty of free cash flow to back up its statutory profit numbers. Because of this, we think LifeVantage's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. At Simply Wall St, we found 1 warning sign for LifeVantage and we think they deserve your attention. This note has only looked at a single factor that sheds light on the nature of LifeVantage's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
29-04-2025
- Business
- Business Insider
LifeVantage (LFVN) Receives a Buy from Lake Street
In a report released yesterday, Brooks O'Neil from Lake Street maintained a Buy rating on LifeVantage (LFVN – Research Report), with a price target of $30.00. The company's shares closed yesterday at $12.14. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, O'Neil is an analyst with an average return of -2.4% and a 37.18% success rate. O'Neil covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Tandem Diabetes Care, and LifeMD. Currently, the analyst consensus on LifeVantage is a Moderate Buy with an average price target of $30.00. The company has a one-year high of $27.38 and a one-year low of $5.22. Currently, LifeVantage has an average volume of 224.9K. Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFVN in relation to earlier this year. Most recently, in February 2025, Michael Beindorff, a Director at LFVN sold 5,850.00 shares for a total of $114,309.00.
Yahoo
17-03-2025
- Business
- Yahoo
LifeVantage Expands Global Reach with International Launch of the MB System™
Following the highly successful launch in U.S. market, LifeVantage begins taking its groundbreaking MB System™ internationally SALT LAKE CITY, March 17, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody GLP-1 System™ to international markets. This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the system's success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production. The MB System™, as the product is known internationally, launched on March 15 for both LifeVantage Consultants and Customers in Japan. On the same date, it became available exclusively to Consultants in Australia, New Zealand, Europe, the UK, Mexico, and Thailand. Customers in these regions gain access starting April 25. The MB System™ is designed to naturally activate the body's own GLP-1 production, providing a range of long-term health benefits that expand to weight management and beyond.* 'Consumers worldwide are seeking sustainable health solutions that go beyond short-term, unsustainable weight management,' said Steve Fife, President and CEO of LifeVantage. 'The MB System™ works harmoniously with the body, empowering individuals to naturally enhance their metabolic health in alignment with their lifestyle and wellness objectives.'* Meeting a Growing Global DemandInterest in GLP-1 and metabolic health is rising worldwide. The global GLP-1 pharmaceutical market alone was valued at $53.46 billion in 2024 and is projected to grow at a CAGR of 17.5% from 2025 to 2030, reaching approximately $156.71 billion by 2030**. In many regions, the focus is on holistic wellness, metabolic balance, and overall vitality in addition to weight management. The MB System™ aligns with this perspective by supporting the body's natural ability to regulate metabolism, gut health, and hormone function—key factors in long-term health.* 'The research that is emerging on all the positive health benefits of the GLP-1 hormone continues to excite us,' said Lisa Barnes, Vice President of Research & Development and Regulatory at LifeVantage. 'From gut and digestive benefits, heart and cardiovascular benefits, and the health of other critical organs like the kidneys and liver, GLP-1 is a hormone essential for our longevity and vitality. We are so proud of this product and the clinically shown efficacy in activating the body's own production of the hormone.' Looking Ahead: Future Market ExpansionsEarly this summer, LifeVantage will launch the MB System™ in the Philippines and Taiwan, followed by Canada later in the year, completing the global rollout and reinforcing our commitment to providing natural Activation solutions worldwide. For more information, visit About LifeVantage CorporationLifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.** Public Relations Contact: Jennifer Rumble, CerconeBrownCompany(704) 923-6378 lifevantage@ Investor Relations Contact: Reed Anderson, ICR (646) 277-1260 in to access your portfolio
